MARCoNS and MSH: What My Latest Peer-Reviewed Study Adds to the CIRS Conversation
Many scientific ideas begin as patterns clinicians keep seeing before the research world has fully caught up.
In the CIRS community, one of those patterns has been the relationship between MARCoNS, multiple antibiotic-resistant coagulase-negative staphylococci in the nasal passages, and low alpha-melanocyte stimulating hormone, better known as α-MSH.
For years, many CIRS practitioners have observed that patients with persistent MARCoNS often seem harder to move out of low-MSH physiology. Patients who clear MARCoNS, by contrast, are often observed clinically to have a better chance of recovering MSH and moving forward in treatment.
But clinical observation and peer-reviewed evidence are not the same thing.
That distinction is important, not because clinical observations are unimportant, but because this is how a field matures. A pattern is noticed. A question is formed. Data are gathered. The result is tested, criticized, refined, and placed into the larger scientific conversation.
That is what this paper represents.
The study I co-authored with Dr. Margaret DiTullio, published in Frontiers in Endocrinology, was designed to examine whether this long-standing CIRS observation could be detected quantitatively in a clinical dataset.
It does not answer every question about MARCoNS, MSH, or CIRS.
But it does move an important piece of the conversation into a mainstream scientific setting.
Why MSH Is Worth Paying Attention To
MSH is often discussed in CIRS as if it were simply “low” or “normal,” but biologically, it is much more interesting than that.
α-MSH is a neuroimmune regulatory peptide. It sits at the intersection of inflammation, mucosal immunity, barrier function, antimicrobial defense, metabolism, and pain signaling. In other words, it is not just a hormone floating around in the bloodstream. It is part of a larger regulatory network that helps coordinate how the body responds to stress, microbes, inflammation, and tissue-level immune activity.
That makes MSH especially interesting in CIRS, where the clinical picture often involves immune activation, inflammatory signaling, mucosal disruption, microbial colonization, food and environmental reactivity, and neurological symptoms.
At the same time, it is important to be honest about the state of the science. MSH is not fully characterized in human chronic illness. There is a strong body of basic science and preclinical work around melanocortin biology, but we do not yet have a complete mainstream clinical framework for understanding what low MSH means across complex chronic inflammatory states.
That is part of why this paper matters.
It gives us one more piece of human clinical data in an area where mainstream science and medicine need much more.
MARCoNS: Not a Classic Infection, But Not Nothing Either
One of the nuances I think is easy to miss is that MARCoNS is not best understood as a classic acute infection.
When people hear “bacteria,” they often think in very binary terms: either there is an infection, or there is nothing clinically meaningful happening.
But biology is rarely that simple.
MARCoNS are commonly found on the skin and mucosal surfaces, including the nose. They are often considered lower-virulence organisms compared with more aggressive pathogens like Staphylococcus aureus.
So the question is not whether MARCoNS behaves like a dramatic acute infection. In most cases, it does not.
The more interesting question is whether persistent nasal colonization can still matter in a vulnerable host.
Colonization simply means that organisms are present and persisting on a surface. It does not automatically mean acute disease. But it also does not automatically mean neutrality. Some organisms can persist quietly while forming biofilms, resisting antibiotics, interacting with antimicrobial peptides, and creating ongoing low-grade immune interaction at the mucosal surface.
That is the middle space MARCoNS may occupy in CIRS.
Not a medical emergency.
Not necessarily a harmless passenger.
Potentially, a persistent microbial signal interacting with a system already struggling to regulate inflammation and neuroimmune balance.
That was one of the deeper ideas sitting underneath this paper.
What We Asked
The main question was simple:
When CIRS patients clear MARCoNS, do their MSH levels recover more than in patients who remain MARCoNS-positive?
We also wanted to know whether this was specific to MSH or whether MARCoNS clearance simply tracked with broad improvement across several biomarkers.
So we looked at three markers commonly followed in CIRS care:
● α-MSH
● MMP-9
● VIP
The study included 188 adult patients treated in Dr. DiTullio’s clinic. All patients were MARCoNS-positive at baseline. Each patient had two timepoints of data: baseline labs and follow-up labs after a period of CIRS treatment that included MARCoNS-directed care.
Patients were then grouped based on whether MARCoNS had cleared by follow-up.
What We Found
Across the full group, all three biomarkers moved in the expected direction over time.
MSH increased.
MMP-9 decreased.
VIP increased.
That already tells us something interesting: this was a clinical cohort where measurable inflammatory and neuroendocrine markers shifted over the course of treatment.
But the more specific finding was this:
Patients who cleared MARCoNS showed greater MSH recovery than patients who remained MARCoNS-positive.
That same MARCoNS-specific pattern was not seen for MMP-9 or VIP. Those markers improved broadly, but they did not separate by MARCoNS clearance in the same way.
To me, that is the most interesting part of the paper.
The signal was not simply, “patients got better.” It was more specific than that. MARCoNS clearance appeared to track most clearly with MSH, not with every biomarker we examined.
That does not prove that MARCoNS causes low MSH.
It does not prove that clearing MARCoNS directly restores MSH.
It does not tell us whether patients felt better, because symptoms were not measured in this dataset.
But it does suggest that the MARCoNS–MSH relationship may be more than a loose clinical impression. In this cohort, it showed up as a measurable and selective association.
Why That Selectivity Matters
In chronic illness research, broad improvement can be hard to interpret.
Patients may be changing environments. They may be using binders. They may be treating MARCoNS. They may be correcting inflammatory markers. They may be at different stages of care. In real-world clinical medicine, many things are happening at once.
That is why I find the selectivity of the MSH signal meaningful.
If MARCoNS clearance had been associated with larger changes in every marker, the result would be harder to interpret. It might simply reflect a general “these patients improved more” pattern.
Instead, the association was specific to MSH, even after attempting to account for multiple confounders in the study, including age, gender, baseline group differences, confounding treatments, and statistical biases like regression to the mean.
That makes the finding more biologically interesting. It suggests that persistent nasal colonization may have a more specific relationship with melanocortin-linked neuroimmune regulation than with every marker used in CIRS care.
That is not the end of the story.
But it is a better question than we had before.
What the Paper Cannot Tell Us Yet
This is where the humility of the paper matters.
This study was retrospective and observational. It was based on real-world clinical data. That means we cannot isolate every variable or make strong causal claims.
We also did not measure symptoms in this dataset. So we cannot say whether changes in MSH corresponded to improvements in fatigue, cognition, pain, sleep, food tolerance, environmental sensitivity, or quality of life.
That part matters deeply.
Patients do not live inside biomarker charts. They live inside bodies, homes, relationships, jobs, and daily decisions shaped by what their nervous and immune systems can tolerate.
So while biomarkers are useful, they are only part of the story.
A next step is to connect these biological patterns to meaningful symptom outcomes.
What This Paper Represents for Patients
For patients, I think this paper has three practical meanings.
First, it helps further validate patient suffering through a clinically useful framework: CIRS. Many patients have symptoms that are real, disabling, and biologically complex, but difficult to explain through conventional categories alone. This paper does not prove the entire CIRS model, but it does show that CIRS-based clinical patterns can be studied in mainstream peer-reviewed journals.
Second, it helps patients connect persistent issues with neuroendocrine dysfunction. This means that patients should consider asking practitioners to pay close attention to what is happening in their sinuses.
Third, it gives patients a better tool for education. Many patients need to explain CIRS not only to doctors, but also to family members, friends, employers, and other professionals who may not understand why environmental illness, sinus colonization, immune markers, and neuroendocrine abnormalities are being discussed together. This paper gives them a peer-reviewed reference point. It helps move the conversation away from “this is just a theory” and toward “this is an emerging clinical framework with specific biological claims that can be tested.”
For patients, that is the value of this paper. Not as a final answer, and not as proof of everything, but as a clearer bridge between lived suffering, clinical pattern recognition, and published science.
What This Paper Represents for Practitioners
For practitioners, I think this paper has a different set of implications.
First, it offers further justification for using CIRS as a clinically useful framework. Many complex chronic illness patients present with patterns that are hard to organize through conventional categories alone. CIRS gives practitioners a way to connect exposure history, inflammatory markers, neuroendocrine abnormalities, microbial colonization, and treatment response into a more coherent clinical picture.
Second, it supports the clinical decision making process of treating sinus microbial colonizations through CIRS-informed principles. In a CIRS context, the question is whether persistent colonization, biofilm behavior, antimicrobial resistance, and mucosal immune disruption may be contributing to broader neuroimmune and neuroendocrine dysregulation.
Third, it provides an opportunity to practice reading empirical papers through a critical lens. The strength of the paper is the selective association: MARCoNS clearance tracked more clearly with MSH recovery than with MMP-9 or VIP. But the limitations also matter: the study was retrospective, symptoms were not measured, and causation was not established. Both sides are part of reading and properly assessing the quality of a paper.
Fourth, it helps clarify where CIRS is in the process of gaining broader legitimacy. This paper does not mean CIRS has suddenly achieved full mainstream acceptance. That is not how medical consensus usually works. Acceptance tends to move incrementally: one careful study, one testable claim, one peer-reviewed publication, one small discovery at a time.
Finally, it encourages us to move away from advocacy-driven language and toward curiosity-driven science. The goal is not to force certainty around CIRS. The goal is to ask better questions, make more precise claims, publish stronger data, and let the scientific process do what it does best when given a real signal to examine.
A Step Forward
I see this paper as a step, not a finish line.
It takes a long-standing clinical observation and gives it a more formal scientific footing. It shows that MARCoNS clearance was selectively associated with greater MSH recovery in this cohort. It also leaves many important questions open.
That balance is important to me.
CIRS research does not need exaggerated certainty. It needs careful, cumulative science that is strong enough to contribute something real and honest enough to define its limits.
For patients, this paper offers validation that some of the biology discussed in CIRS care can be studied seriously.
For practitioners, it offers a more grounded way to think about MARCoNS, MSH, and the nasal microbiome.
And for researchers, it opens the door to the next set of questions: How does persistent nasal colonization interact with neuroimmune regulation? Which organisms matter most? Does MSH recovery track with symptom improvement? And how can we design better prospective studies to test these relationships more directly?
That is what this paper represents to me.
Not the final word.
A stronger place to begin.
Paper Reference
DiTullio, M., & Navarro-Torres, C. A. (2026). Clearance of multiple antibiotic-resistant coagulase-negative staphylococci is selectively associated with higher circulating α-melanocyte stimulating hormone in patients evaluated for chronic inflammatory response syndrome. Frontiers in Endocrinology, 17, 1728408. https://doi.org/10.3389/fendo.2026.1728408
This post is for informational and educational purposes only and does not constitute medical advice.
